Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: A meta-analysis

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Ayieko, James ^a,d   Abuogi, Lisa ^b   Simchowitz, Brett ^c,d   Bukusi, Elizabeth A ^a   Smith, Allan H ^d   Reingold, Arthur ^d  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b University of Colorado Denver and Children s Hospital Colorado   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Children; Efficacy; Isoniazid; Meta analysis; Prophylaxis; Tuberculosis

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

AGE DISTRIBUTION; ARTICLE; CHILD; CHILDHOOD MORTALITY; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENDEMIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANCY; META ANALYSIS; MORBIDITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; ADOLESCENT; INFANT; MICROBIOLOGY; PRESCHOOL CHILD; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; HIV INFECTIONS; HUMANS; INFANT; ISONIAZID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84896714501     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-91     Document Type: Article

References (38)

1. Kumar V, Abbas AK, Fausto N, Mitchell RN. Robbins Basic Pathology 2007, 516-522. Philadelphia: Saunders Elsevier, 8.
2. World Health Organization Global Tuberculosis Report 2012, Geneva, Switzerland: WHO, World Health Organization.
3. World Health Organization Retention in HIV Programmes, Defining the Challenges and Identifying Solutions 2011, Geneva, Switzerland: WHO, World Health Organization.
4. Beyers N, Gie RP, Schaaf HS, Van Zyl S, Talent JM, Nel ED, Donald PR. A prospective evaluation of children under the age of 5 years living in the same household as adults with recently diagnosed pulmonary tuberculosis. Int J Tuberc Lung Dis 1997, 1:38-43.
5. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, Enarson DA, Donald PR, Beyers N. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004, 8:392-402.
6. Rieder HL. Epidemiology of tuberculosis in children. Annales Nestlé 1997, 55:1-9.
7. Ferebee SH. Chemoprophylaxis of tuberculosis. Bull N Y Acad Med 1960, 36:470-474.
8. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, Battegay M. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999, 13(4):501-507.
9. Gray DM, Zar H, Cotton M. Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children. Cochrane Database Syst Rev 2009, 1:CD006418.
10. Cochrane Reviewers Handbook 4.1.6.The Cochrane Library 2003, Clarke M, Oxman AD, Issue 1.
11. Greenland S. Meta-analysis. Modern Epidemiology 1998, 643-673. Philadelphia: Lippincott-Raven, Rothman KJ, Greenland S.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
13. Petitti D. Meta-analysis, Decision Analysis and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine 1994, New York: Oxford University Press.
14. Shore RE, Gardner MJ, Pannett B. Ethylene oxide: an assessment of the epidemiological evidence on carcinogenicity. Br J Ind Med 1993, 50:971-997.
15. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
16. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. Br Med J 1997, 315:629-634.
17. Begg CB. Publication bias. Handbook of Research Synthesis 1994, 399-409. New York: Russell Sage Foundation, Cooper H, Hedges LV.
18. Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, Rabie H, Lombard CJ. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomized controlled trial. BMJ 2007, 334:136-142.
19. Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, Jean-Philippe P, McSherry G, Mitchell C. Primary isoniazid prophylaxis in HIV exposed children. N Engl J Med 2011, 365(1):21-31.
20. Egsmose T, Ang'awa JO, Poti SJ. The use of isoniazid among household contacts of open cases of pulmonary tuberculosis. Bull World Health Organ 1965, 33(3):419-433.
21. Mount FW, Ferebee SH. Preventive effects of isoniazid in the treatment of primary tuberculosis in children. N Engl J Med 1961, 12(265):713-721.
22. Debre R, Perdrizet S, Lotte A, Naveau M, Lert F. Isoniazid chemoprophylaxis of latent primary tuberculosis: in five trial centres in France from 1959 to 1969. Int J Epidemiol 1973, 2(2):153-160.
23. Comstock GW. Isoniazid prophylaxis in an undeveloped area. Am Rev Respir Dis 1962, 86:810-822.
24. Gupta DK, Kumar R, Nath N, Kothari AK. Chemoprophylaxis in high risk children analysis of 8 years' follow up: preliminary report. Ind J Tub 1993, 40(107):125-127.
25. Mount FW, Ferebee SH. Preventive effects of isoniazid in the treatment of primary tuberculosis in children. New Eng J Med 1961, 265:713.
26. Zhu R, Kiser JJ, Seifart HI, Werely CJ, Mitchell CD, D'Argenio D, Fletcher CV. The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol 2012, 52(4):511-519.
27. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000, 2:CD001363.
28. Aït-Khaled N, Alarcon E, Bissell K, Boillot F, Caminero JA, Chiang CY, Clevenbergh P, Dlodlo R, Enarson DA, Enarson P, Ferroussier O, Fujiwara PI, Harries AD, Heldal E, Hinderaker SG, Kim SJ, Lienhardt C, Rieder HL, Rusen ID, Trébucq A, Van Deun A, Wilson N. Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. Int J Tuberc Lung Dis 2009, 13(8):927-935.
29. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010, 1:CD000171.
30. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 1962, 85:490.
31. Mount FW, Ferebee SH. The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis. Am Rev Respir Dis 1962, 85:821.
32. Groth-Peterson E, Gad U, Ostergaard F. Mass chemoprophylaxis of tuberculosis: the acceptability and untoward side effects of isoniazid in a control study in Greenland. Am Rev Respir Dis 1960, 81:643.
33. Mills HL, Cohen T, Colijn C. Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis. Sci Transl Med 2013, 5(180):180ra49.
34. World Health Organization Guidelines for Intensive Tuberculosis Case Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource-Constrained Settings 2011, Geneva, Switzerland: WHO, World Health Organization.
35. Jadad AR, Moore RA, Caroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
36. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000, 53:207-216.
37. Roger M, Ross J, Jonathan A. Updated tests for small-study effects in meta-analyses. Stata J 2009, 9(2):197-210.
38. Graham SM, Ahmed T, Amanullah F, Browning R, Cardenas V, Casenghi M, Cuevas LE, Gale M, Gie RP, Grzemska M, Handelsman E, Hatherill M, Hesseling AC, Jean-Philippe P, Kampmann B, Kabra SK, Lienhardt C, Lighter-Fisher J, Madhi S, Makhene M, Marais BJ, McNeeley DF, Menzies H, Mitchell C, Modi S, Mofenson L, Musoke P, Nachman S, Powell C, Rigaud M, Rouzier V, Starke JR, Swaminathan S, Wingfield C. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis 2012, 205(2):199-208.